NuCana plc American Depositary Share (NCNA)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with business quality. NuCana is an $8.9 million market-cap clinical-stage biopharmaceutical company with 10 employees. It is developing ProTide-based cancer medicines, including NUC-3373, but the data show no commercial revenue stream and no revenue growth figure. A pipeline is not a moat; without approved products or pricing power, I cannot identify durable competitive protection. Financial health is poor. Trailing free cash flow is -$5.3 million, a -60.1% FCF yield against market cap. ROE is -70.26%, ROCE -43.49%, Altman Z-score -11.98, and Piotroski F-score 1/9. The low D/E of 0.03 helps, but cash burn dominates. Valuation looks statistically extraordinary: at the 2026-10-13 close of $1.05, FairStock P/E is 0.02 and P/B is 0.17. Graham Number is $96.99, implying 98.92% margin of safety, but Graham would demand reliable earnings and assets. The low P/E needs filed-period earnings verification, especially with a FairStock score of 37/100 and no Lynch category because there are only 0 years of filed results versus the required 3. Growth trajectory is speculative: the supplied profit-growth figure has no filed period in my data, and the 52-week range of $0.95-$5.65 with beta 2.24 shows volatility. This is a lottery-like biotech, not a compounding business I can underwrite.

In plain English: NuCana is a tiny drug-development company with 10 employees working on new cancer treatments. The data show it is not yet a strong business: it loses money, burns cash, and has weak safety and profitability scores. The share price looks very cheap compared with some of its accounting numbers, but that likely reflects high risk rather than a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer